NovoCure Ltd
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
NVCR$12.53-5.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets as of
| December 31, | ||
|---|---|---|
| U.S. dollars in thousands | 2024 | 2023 |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $163,767 | $240,821 |
| Short-term investments | 796,106 | 669,795 |
| Restricted cash | 2,327 | 1,743 |
| Trade receivables, net | 74,226 | 61,221 |
| Receivables and prepaid expenses | 35,063 | 22,677 |
| Inventories | 35,086 | 38,152 |
| Total current assets | 1,106,575 | 1,034,409 |
| Long-term assets: | ||
| Property and equipment, net | 77,660 | 51,479 |
| Field equipment, net | 14,811 | 11,384 |
| Right-of-use assets | 27,120 | 34,835 |
| Other long-term assets | 14,618 | 14,022 |
| Total long-term assets | 134,209 | 111,720 |
| Total assets | $1,240,784 | $1,146,129 |
| December 31, | ||
|---|---|---|
| U.S. dollars in thousands, except share and per share data | 2024 | 2023 |
| Liabilities and shareholders’ equity | ||
| Current liabilities: | ||
| Convertible note | $558,160 | $— |
| Trade payables | $105,086 | $94,391 |
| Other payables, lease liabilities and accrued expenses | 93,130 | 84,724 |
| Total current liabilities | 756,376 | 179,115 |
| Long-term liabilities: | ||
| Convertible note | — | 568,822 |
| Senior secured credit facility, net | 97,300 | — |
| Long term leases | 19,971 | 27,420 |
| Employee benefit liabilities | 6,940 | 8,258 |
| Other long-term liabilities | 18 | 18 |
| Total long-term liabilities | 124,229 | 604,518 |
| Total liabilities | 880,605 | 783,633 |
| Commitments and contingencies | ||
| Shareholders’ equity: | ||
| Share capital - | ||
| Ordinary shares - No par value, Unlimited shares authorized; Issued and outstanding: 108,516,819 shares and 107,075,754 shares at December 31, 2024 and December 31, 2023 respectively; | — | — |
| Additional paid-in capital | 1,519,809 | 1,353,468 |
| Accumulated other comprehensive income (loss) | (5,500) | (5,469) |
| Retained earnings (accumulated deficit) | (1,154,130) | (985,503) |
| Total shareholders’ equity | 360,179 | 362,496 |
| Total liabilities and shareholders’ equity | $1,240,784 | $1,146,129 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.